320 related articles for article (PubMed ID: 28533658)
1. Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality.
Kourie HR; Tabchi S; Ghosn M
World J Gastroenterol; 2017 May; 23(17):3017-3021. PubMed ID: 28533658
[TBL] [Abstract][Full Text] [Related]
2. GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers.
Collienne M; Loghmani H; Heineman TC; Arnold D
Future Oncol; 2022 Aug; 18(26):2871-2878. PubMed ID: 35796248
[TBL] [Abstract][Full Text] [Related]
3. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies.
Moehler M; Göpfert K; Lenz HJ
Oncol Res Treat; 2018; 41(5):313-315. PubMed ID: 29705792
[TBL] [Abstract][Full Text] [Related]
4. Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies.
Mazloom A; Ghalehsari N; Gazivoda V; Nimkar N; Paul S; Gregos P; Rateshwar J; Khan U
J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32781500
[TBL] [Abstract][Full Text] [Related]
5. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.
Neuzillet C; Rousseau B; Kocher H; Bourget P; Tournigand C
Pharmacol Ther; 2017 Jun; 174():145-172. PubMed ID: 28223233
[TBL] [Abstract][Full Text] [Related]
6. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.
El Dika I; Ilson DH
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1085-1092. PubMed ID: 30092682
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors side effects and management.
Kourie HR; Klastersky J
Immunotherapy; 2016 Jun; 8(7):799-807. PubMed ID: 27349979
[TBL] [Abstract][Full Text] [Related]
8. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies.
Zhang Y; Xu J; Zhang N; Chen M; Wang H; Zhu D
Cancer Lett; 2019 Aug; 458():123-135. PubMed ID: 31121212
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy in gastrointestinal malignancies.
Haller DG
Semin Oncol; 1988 Jun; 15(3 Suppl 4):50-64. PubMed ID: 3293219
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
Cheung PF; Lutz M; Siveke JT
Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Gastrointestinal Malignancies.
Mizrahi J; Pant S
Adv Exp Med Biol; 2020; 1244():93-106. PubMed ID: 32301012
[TBL] [Abstract][Full Text] [Related]
12. Aquaporins: Their role in gastrointestinal malignancies.
Nagaraju GP; Basha R; Rajitha B; Alese OB; Alam A; Pattnaik S; El-Rayes B
Cancer Lett; 2016 Apr; 373(1):12-18. PubMed ID: 26780474
[TBL] [Abstract][Full Text] [Related]
13. Cautious optimism-the current role of immunotherapy in gastrointestinal cancers.
Mendis S; Gill S
Curr Oncol; 2020 Apr; 27(Suppl 2):S59-S68. PubMed ID: 32368175
[TBL] [Abstract][Full Text] [Related]
14. Role of ion channels in gastrointestinal cancer.
Anderson KJ; Cormier RT; Scott PM
World J Gastroenterol; 2019 Oct; 25(38):5732-5772. PubMed ID: 31636470
[TBL] [Abstract][Full Text] [Related]
15. [Cytotoxic Agents and Immune Checkpoint Inhibitors].
Kawazoe A; Shitara K
Gan To Kagaku Ryoho; 2017 Sep; 44(9):717-721. PubMed ID: 28912395
[TBL] [Abstract][Full Text] [Related]
16. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer.
Filippi R; Lombardi P; Depetris I; Fenocchio E; Quarà V; Chilà G; Aglietta M; Leone F
Expert Opin Pharmacother; 2018 Sep; 19(13):1451-1463. PubMed ID: 30161003
[TBL] [Abstract][Full Text] [Related]
17. Next-Generation Approaches to Immuno-Oncology in GI Cancers.
Hecht JR; Mitchell J; Morelli MP; Anandappa G; Yang JC
Am Soc Clin Oncol Educ Book; 2023 Jun; 43():e389072. PubMed ID: 37290032
[TBL] [Abstract][Full Text] [Related]
18. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
Azoury SC; Gilmore RC; Shukla V
Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032
[TBL] [Abstract][Full Text] [Related]
20. Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.
Habre M; Habre SB; Kourie HR
Immunotherapy; 2016 Dec; 8(12):1437-1446. PubMed ID: 28000535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
